MedBiome partners its advanced microbiome technology, called RapidAIM, to enable drug discovery, compound screening and to support the development needs of pharmaceutical and biotech companies.

• focuses on screening compounds against individual microbiomes (human and animals).
• develops compound libraries that can reach the gut microbiome.
• provides industry-leading functional metaproteomics, metagenomics and metabolomics approaches.
• provides leading bioinformatics and software tools to assess the effects of drugs on the microbiome.

For more information about MedBiome and interests in collaborations Please contact us at:info@medbiome.ca